Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Cardiac Failure

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cardfail.2012.07.009PMID 23040117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.

  2012cited by this paper
• Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients.

  2012cited by this paper
• GLP-1 and cardioprotection: from bench to bedside.

  2012cited by this paper
• Cardiovascular effects of glucagonlike peptide-1 agonists.

  2011cited by this paper
• DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion

  2011cited by this paper
• Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

  2011cited by this paper
• Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

  2010cited by this paper
• Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy.

  2010cited by this paper
• GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats

  2010cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• From bench to bedside: a novel technique of acquiring OCT images.

  2008cited by this paper
• Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Metabolic syndrome and risk for heart failure in middle-aged men

  2006cited by this paper
• Cardiomyopathy of insulin resistance.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

  2006cited by this paper
• New therapies for type 2 diabetes based on glucagon-like peptide 1.

  2006cited by this paper
• Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts

  2006cited by this paper
• A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.

  2006cited by this paper
• Insulin resistance and risk of congestive heart failure.

  2005cited by this paper
• Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment

  2005cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005cited by this paper
• The Evolving Diabetes Burden in the United States

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• Clinical research: heart failureInsulin resistance in idiopathic dilated cardiomyopathy: A possible etiologic link

  2004cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Diabetes and idiopathic cardiomyopathy: a nationwide case-control study.

  2003cited by this paper
• Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Insulin resistance in dilated cardiomyopathy.

  2003cited by this paper
• PET myocardial glucose metabolism and perfusion imaging: Part 1-Guidelines for data acquisition and patient preparation.

  2003cited by this paper
• Erratum to PET myocardial glucose metabolism and perfusion imaging: Part I — Guidelines for patient preparation and data acquisition

  2003cited by this paper
• Influence of diabetes mellitus on heart failure risk and outcome

  2003cited by this paper
• Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.

  2002cited by this paper
• Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study.

  2002cited by this paper
• Switching Metabolic Genes to Build a Better Heart

  2002cited by this paper
• Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.

  2002cited by this paper
• Obesity, diabetes, and risk of cardiovascular disease in the elderly.

  2002cited by this paper
• Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.

  2001cited by this paper
• Metabolic Gene Expression in Fetal and Failing Human Heart

  2001cited by this paper
• Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up.

  2001cited by this paper
• Akt Activation Preserves Cardiac Function and Prevents Injury After Transient Cardiac Ischemia In Vivo

  2001cited by this paper
• Glycemic Control and Heart Failure Among Adult Patients With Diabetes

  2001cited by this paper
• Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.

  2000cited by this paper
• Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure.

  2000cited by this paper
• Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.

  2000cited by this paper
• Diabetes and cardiovascular disease

  2000cited by this paper
• Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group.

  1997cited by this paper
• Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

  1997cited by this paper
• Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

  1996cited by this paper
• Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences

  1995cited by this paper
• Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study.

  1994cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus

  2024cites this paper
• DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

  2022cites this paper
• Diabetes Mellitus

  2021cites this paper
• Decreased mortality after long term treatment with DPP-4 inhibitors: A retrospective study of US veterans with type 2 diabetes.

  2021cites this paper
• Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine – Review

  2021cites this paper
• DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism

  2020cites this paper
• Diabetes and Heart Failure: Pathogenesis and Novel Therapeutic Approaches

  2019cites this paper
• Heart Failure with Preserved Ejection Fraction: A Review for the Clinician

  2019cites this paper
• Peptides from chicken processing by-product inhibit DPP-IV and promote cellular glucose uptake: potential ingredients for T2D management.

  2019cites this paper
• Histone Deacetylases and Oxidative Stress: Role in Diabetic Cardiomyopathy

  2019cites this paper
• Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control

  2018cites this paper
• Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking

  2018cites this paper
• Diabetic cardiomyopathy: where we are and where we are going

  2017cites this paper
• Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure.

  2017cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Risk: Retrospective Study of 50 Type 2 Diabetic Patients with Chronic Heart Failure

  2017cites this paper
• Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

  2017cites this paper
• Heart failure with preserved ejection fraction: current management and future strategies

  2017cites this paper
• Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball

  2017cites this paper
• Vasoprotective actions of relaxin in the vascular system

  2016cites this paper
• DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.

  2016cites this paper
• Nucleobindin-2: A Novel Regulator of Immune-Metabolic Interactions

  2016cites this paper
• Cellular effects of the soluble guanylate cyclase stimulator (sGC) BAY 41-8543 in a model of heart failure with preserved ejection fraction (HFPEF)

  2016cites this paper
• Neue Therapiekonzepte zur Herzinsuffizienz mit erhaltener Ejektionsfraktion

  2015cites this paper
• Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.

  2015influential citation
• Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure

  2015cites this paper
• Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes

  2015cites this paper
• Targeting metabolic disturbance in the diabetic heart

  2015cites this paper
• Mononuclear cells and vascular repair in HHT

  2015cites this paper
• Prevention of myocardial stunning during percutaneous coronary interventions: novel insights from pre-treatment with glucagon-like peptide-1.

  2015cites this paper
• Papel da dipeptidil peptidase IV na fisiopatologia da insuficiência cardíaca

  2015cites this paper
• Targeting metabolic disturbance in the diabetic

  2015cites this paper
• [New therapy concepts for heart failure with preserved ejection fraction].

  2015cites this paper
• Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection

  2014cites this paper
• Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited

  2014cites this paper
• Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management.

  2013cites this paper
• The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives

  2013cites this paper
• Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.

  2013cites this paper